Leading investigators affiliated with US Oncology Research involved in six oral clinical study presentations, 19 posters and two publications
The Woodlands, Texas (Dec. 6, 2013) — More than 25 leading investigators affiliated with US Oncology Research participated in 26 studies that will be presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, La. at the Ernest N. Morial Convention Center. ASH will take place Dec. 7-10 and is an educational and scientific program that helps hematology professionals stay up-to-date on the latest research, therapies, and tools needed to be successful in their field.
Roger Lyons, M.D., F.A.C.P., medical oncologist/ hematologist and president of Cancer Care Centers of South Texas (CCCST), an affiliate of US Oncology Research, is co-author of two studies being featured as oral presentations. One study titled Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients will be presented on Dec. 9 at 7:00am and will take an in-depth look into whether recently approved anti-coagulants are effective in cancer patients who experience blood clots.
Dr. Lyons is also co-author of the study titled Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-1, which will be featured as an oral presentation on Dec. 9 at 11:45am. This is a follow up to a previous study that led to the approval of Ruxolitinib, a JAK-2 inhibitor, as the only treatment for Myelofibrosis. Dr. Lyons says this trial studied patients during a longer period of time to take a more in-depth look at the drug’s efficacy, toxicity and survival outcomes.
“I believe we are entering into an exciting era where, during the next five to eight years, we will see enormous numbers of small, targeted studies focused on improving treatments for hematologic diseases and blood disorders,” said Dr. Lyons. “These could be dramatic and game changing, which is always exciting for physicians and, most importantly, for patients. Hematology continues to be at the forefront of innovation, advanced treatment options and new approaches. This is evident by the number of high-quality findings being presented at meetings such as ASH.”
In addition to the two studies above, 24 other US Oncology Research affiliated studies will be featured as oral presentations, posters or publications at this year’s meeting. A full list of US Oncology Research affiliated studies on display at the ASH Annual Meeting is below. For more information or to interview an investigator, contact US Oncology Research Public Relations Manager, Claire Crye at 281-825-9927.
Oral
Presentations:
1. Monday, Dec. 9:
7:00am, Room 278-282, #211
Edoxaban For Long-Term Treatment Of Venous
Thromboembolism In Cancer Patients
Gary E. Raskob, Harry
Buller, Pantep Angchaisuksiri, Doyeun Oh, Zoltan Boda, Roger M. Lyons, Jeffrey I. Weitz, George Zhang, Hans J. Lanz,
Michele Mercuri
2. Monday, Dec. 9:
11:30am, La Nouvelle Ballroom AB, #371
A Phase III Study Of Enzastaurin In Patients With
High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary
Treatment: The Prelude Trial
Michael
Crump, Sirpa Leppä, Luis E. Fayad, Je-Jung Lee, Alice Di
Rocco, Michinori Ogura, Hans Hagberg, Frederick Schnell, Robert M. Rifkin, Andreas Mackensen, Fritz Offner, Lauren
Pinter-Brown, Sonali M. Smith, Kensei Tobinai, Su-Peng Yeh, Jun Zhu, Marjo
Hahka-Kemppinen, Donald Thornton, Peipei Shi, Boris Lin, Brad S. Kahl, Norbert
Schmitz, Kerry J. Savage, Thomas M. Habermann
3. Monday, Dec. 9:
11:45am, New Orleans Theatre C, #396
Long-Term Outcomes Of Ruxolitinib Therapy In Patients With
Myelofibrosis: 3-Year Update From COMFORT-I
Srdan Verstovsek, Ruben A.
Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. Dipersio, John
V. Catalano, Michael W. Deininger, Carole B. Miller, Richard T. Silver, Moshe
Talpaz, Elliott F. Winton, Jimmie H. Harvey, Jr., Murat O. Arcasoy, Elizabeth
Hexner, Roger M. Lyons, Ronald
Paquette, Azra Raza, Kris Vaddi, William Sun, Wei Peng, Victor A. Sandor, Hagop
M. Kantarjian
4. Monday, Dec. 9:
4:00pm, Room 220-222, #528
Ofatumumab + Chlorambucil Versus Chlorambucil Alone In
Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The
Phase III Study Complement 1 (OMB110911)
Peter Hillmen, Tadeusz
Robak, Ann Janssens, K. Govindbabu, Sebastian Grosicki, Jiri Mayer, Panagiotis
Panagiotidis, Eva Kimby, Anna Schuh, Thomas
Boyd, Marco Montillo, Astrid McKeown, Jodi L. Carey, Ira V. Gupta, Chai-Ni
Chang, Steen Lisby, Fritz Offner
5. Tuesday, Dec.
10: 7:30am-9:00am, Hall F, #LBA-6
A Phase 3, Randomized, Double-Blind, Placebo-Controlled
Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for
Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
Richard
R. Furman, Jeff P. Sharman, Steven E. Coutre, Bruce D.
Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D.
Zelenetz, Thomas J. Kipps, Ian Flinn, Paolo Ghia, Herbert Eradat, Thomas Ervin,
Nicole Lamanna, Michael Hallek, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma,
Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L.
Miller, Daniel Li, Thomas M. Jahn, Roger D. Dansey, Susan M. O'Brien
6. Tuesday, Dec.
10: 7:45am, La Nouvelle Ballroom AB, #848
A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed
Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With
DLBCL And Other B-Cell Lymphomas
Nancy L. Bartlett, Jeff P. Sharman, Yasuhiro
Oki, Ranjana H. Advani, Celeste M. Bello, Jane N. Winter, Yin Yang, Dana A.
Kennedy, Eric D. Jacobsen
Posters:
7. Saturday, Dec. 7: 5:30pm-7:30pm,
Hall E, #1634
Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In
Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
Jeff P. Sharman, Leonard Klein, Michael Boxer, Kathryn S. Kolibaba, Michael
J. Hawkins, Julie A. Di Paolo, Jing Hu, Anita Reddy, Feng Jin, Flordeliza
Melchor-Khan, Christopher A. Yasenchak
8. Saturday, Dec. 7: 5:30pm-7:30pm,
Hall E, #1630
Phase 1 Study Of Single Agent CC-292, a Highly Selective
Bruton’s Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic
Leukemia (CLL)
Jennifer R. Brown, Wael A. Harb, Brian T. Hill,
Janice Gabrilove, Jeff P. Sharman, Marshall
T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger,
Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Evelyn Barnett, Jeffrey Marine,
Pilar Nava-Parada, Ada Azaryan, Jay Mei, Thomas J. Kipps
9. Saturday, Dec. 7: 5:30pm-7:30pm,
Hall G, #1941
Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and
Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma
(MM)
Robert M. Rifkin, Clara Chen, Rahul Dhanda, Debra
Rembert, Abbie Ba-Mancini, Esprit Ma, Yanyan Zhu, Edward
Dow, Liviu Niculescu
10. Saturday, Dec. 7: 5:30pm-7:30pm,
Hall G, #1966
Efficacy and Safety Of Three Bortezomib-Based Induction
and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple
Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US
Community-Based UPFRONT Study (NCT00507416)
Ruben Niesvizky, Ian Flinn, Robert
M. Rifkin, James Essell, Yousuf Gaffar, Thomas Warr, Rachel Neuwirth, Abbie Ba-Mancini, Yanyan
Zhu, Liviu Niculescu, James Reeves
11. Saturday, Dec. 7: 5:30pm-7:30pm,
Hall G, #1934
A Phase 1, Dose-Escalation Study (CHAMPION-1)
Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients
With Relapsed Or Refractory Multiple Myeloma
James R. Berenson, Leonard Klein, Robert M. Rifkin, Priti
Patel, Sandra Dixon, Ying Ou, Alan Cartmell
12. Saturday, Dec. 7: 5:30pm-7:30pm,
Hall E, #1632
Clinical Activity Of Idelalisib (GS-1101), A Selective
Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia
(CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1
Mutation
Steven E. Coutre, John P. Leonard, Jacqueline C.
Barrientos, Sven De Vos, Ian Flinn, Richard R. Furman, Jennifer R. Brown, Nina
Wagner-Johnston, Don M. Benson, Jr., Marshall T. Schreeder, Jeff P. Sharman, Thomas Boyd, Stephen
Spurgeon, Andrew D. Zelenetz, Nicole Lamanna, Thomas J. Kipps, Brad S. Kahl,
Celeste M. Bello, Jan A. Burger, Kanti R. Rai, Roger D. Dansey, Yeonhee Kim,
Leanne M. Holes, Mirella Lazarov, Ronald L. Dubowy, Susan M. O'Brien
13. Sunday, Dec. 8: 6:30pm-8:30pm,
Hall G, #3207
Response To First-Line Treatment In Stem Cell Transplant
(SCT) and Non-SCT Patients With Newly Diagnosed Multiple Myeloma Who Are Enrolled
In The Connect MM Registry
Rafat Abonour, Jatin J. Shah, Brian Durie, Howard Terebelo,
Cristina J. Gasparetto, Jayesh Mehta, Mohit Narang, Sachdev P. Thomas, Kathleen
Toomey, Kristen A Sullivan, Shankar Srinivasan, Yasir Nagarwala, Robert M. Rifkin
14. Sunday, Dec. 8: 6:30pm-8:30pm,
Hall E, #2733
Association Between Treatment Adherence and Response Among
Patients With Chronic Myeloid Leukemia (CML) Receiving First-Line TKIs In The
Community Setting
Nicholas J. Di
Bella, Debajyoti Bhowmik, Menaka Bhor, Mark Yap, Brooke Middlebrook, Debra Rembert, Rahul Dhanda, Zachary
Cain, Tony Okoro, Bjorn Bolinder, Debra
Patt, Elias J. Jabbour
15. Sunday, Dec. 8: 6:30pm-8:30pm,
Hall E, #2775
48-Month Update On Survival and AML Transformation In a
600-Patient Registry Of Lower-Risk MDS Patients
Roger M. Lyons, Billie J. Marek, Carole S.
Paley, Jason Esposito, Katie McNamara, Lawrence
Garbo, Nicholas DiBella, Guillermo Garcia-Manero
16. Sunday, Dec. 8: 6:30pm-8:30pm,
Hall E, #2978
The VIP (Very Immunocompromised Patient) Protocol:
Improved Access To Care and Time To Antibiotics
Paul J. Shaughnessy, Ann Kelley, Roberta Tremper,
Jonathan Tinker, Carlos Bachier, Joseph Holahan, Roger M. Lyons, Charles F. LeMaistre
17. Sunday, Dec. 8: 6:30pm-8:30pm,
Hall E, #2878
Idelalisib, a Selective Inhibitor Of PI3Kδ, In
Combination With Bendamustine,
Fludarabine or Chlorambucil In Patients With Relapsed Or Refractory (R/R)
Chronic Lymphocytic Leukemia (CLL)
Sven De Vos, Richard R. Furman, Jacqueline C. Barrientos, Nina
D. Wagner-Johnston, Ian Flinn, Jeff P.
Sharman, Thomas Boyd, John P. Leonard, Roger D. Dansey, Yeonhee Kim, Leanne
M. Holes, Ronald L. Dubowy, Steven E. Coutre
18. Sunday, Dec. 8: 6:30pm-8:30pm,
Hall G, #3178
Comparable Outcomes With
Bortezomib-Cyclophosphamide-Dexamethasone (VCD) and
Bortezomib-Lenalidomide-Dexamethasone (VRD) For Initial Treatment Of Newly Diagnosed
Multiple Myeloma (MM)
Shaji K. Kumar, Ann E. Engebretson, Francis K. Buadi, Martha Q.
Lacy, Angela Dispenzieri, Mei Sheng Duh, Marie-Hélène Lafeuille, Patrick
Lefebvre, Wendy Y. Cheng, Katherine Dea, Mark
Yap, Shanmugapriya Saravanan, Iwen Pan, Debra Rembert, Rahul Dhanda, Debra
Patt, Liviu Niculescu, Abbie Ba-Mancini, Esprit Ma, Maureen Quick, S.
Vincent Rajkumar
19. Monday, Dec. 9: 6:00pm-8:00pm,
Hall E, #4176
Chemo-Immunotherapy Combination Of Idelalisib With
Bendamustine/Rituximab Or Chlorambucil/Rituximab In Patients With
Relapsed/Refractory CLL Demonstrates Efficacy and Tolerability
Jacqueline C. Barrientos, Nina D.
Wagner-Johnston, Sven De Vos, Steven E. Coutre, Marshall T. Schreeder, Ian
Flinn, Jeff P. Sharman, Kanti R.
Rai, John P. Leonard, Roger Dansey, Yeonhee Kim, Leanne M. Holes, Henry
Adewoye, Richard R. Furman
20. Monday, Dec. 9: 6:00pm-8:00pm,
Hall E, #4180
A Phase 1 Study Of The Selective PI3Kd Inhibitor
Idelalisib (GS‑1101) In Combination With Therapeutic
Anti-CD20 Antibodies (Rituximab or Ofatumumab) In Patients With Relapsed Or
Refractory Chronic Lymphocytic Leukemia
Richard R. Furman, Sven De Vos, John P. Leonard,
Jacqueline C. Barrientos, Marshall T. Schreeder, Ian W. Flinn, Jeff P. Sharman, Thomas Boyd, Nathan
Fowler, Kanti R. Rai, Yeonhee Kim, Leanne M. Holes, Roger Dansey, Thomas M.
Jahn, Steven E. Coutre
21. Monday, Dec. 9: 6:00pm-8:00pm,
Hall G, #4389
A Phase 2 Study Of Single-Agent Brentuximab Vedotin for
Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above:
Interim Results
Christopher A.
Yasenchak, Robert Chen, Jeff
P. Sharman, Ralph V. Boccia, Beata Holkova, Peter J. Rosen, Jonathan W.
Friedberg, Megan M. O'Meara, Andres Forero-Torres
22. Monday, Dec. 9: 6:00pm-8:00pm,
Hall E, #4163
The Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib
(PCI-32765) Monotherapy Demonstrates Long-term Safety and Durability Of
Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Patients In An Open-Label Extension Study
Susan O'Brien, Richard R. Furman, Nathan Fowler, Steven E. Coutre,
Jeff P. Sharman, Kristie A. Blum, Jan
A. Burger, Jeffrey A. Jones, William G. Wierda, Emiliano Mugnaini, Ian Flinn,
Ranjana H. Advani, Kathryn S. Kolibaba, Yun
Shaw, Fong Clow, Danelle F. James, Alvina D. Chu, John C. Byrd
23. Monday, Dec. 9: 6:00pm-8:00pm,
Hall G, #4342
Safety and Clinical Activity Of Crizotinib In Patients
With ALK-Rearranged Hematologic Malignancies
Carlo Gambacorti-Passerini, Keizo Horibe, Fadi Braiteh, Hui-qiang Huang, Yuankai
Shi, Matthew H. Taylor, Nicoletta Brega, Jolanda Paolini, Paulina Selaru, Tae
Min Kim
24. Monday,
Dec. 9: 6:00pm-8:00pm, Hall E, #4090
Myeloproliferative Neoplasm Quality Of Life (MPN-QOL)
Study Group: Observational Study Of Quality Of Life and Symptomatic Response In
Myelofibrosis Patients Receiving Undergoing Treatment With Conventional
Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms
Trial
Veena Fauble, Robyn M. Emanuel, Holly Lynn Geyer, Amylou
Constance Dueck, Nicolaus Kroeger, Bart L. Scott, Aaron T. Gerds, Uday R.
Popat, Sergio A. Giralt, Vikas Gupta, David Ross, Emily Knight, Ana Kerguelen
Fuentes, Christen Lykkegaard Andersen, Elisabeth Ejerblad, Gunnar Birgegard,
Peter Johansson, Bjorn Andreasson, Federico Sackmann, Jean-Loup Demory,
Constantine S. Tam, Jan J. Michiels, Deepti H. Radia, Michael Boxer, Ruben A. Mesa
25. Monday,
Dec. 9: 6:00pm-8:00pm, Hall G, #4587
Differential Gene Expression Analysis Predicts For Response To
Bortezomib In The Treatment Of Steroid Refractory Chronic Graft-Versus-Host
Disease (cGVHD)
Alan M. Miller, Reva Schneider, Estil A.
Vance, Edward Agura, Sheila Powell, Virginia Pascual,
Indira Munagala, Huanying Qin
Publication:
26. Randomized,
Placebo-Controlled, Phase I/II Trial Of the Thrombopoietin Receptor Agonist
Eltrombopag in Thrombocytopenic Patients with Advanced Myelodysplastic
Syndromes or Acute Myeloid Leukemia – A Subgroup Analysis of Patients
Receiving Concomitant Anticancer Therapy
Uwe Platzbecker,
Raymond S.M. Wong, Amit Verma, Camille Abboud, Sergio Araujo, Tzeon-Jye Chiou,
John Feigert, Su-Peng Yeh, Katharina Götze, Norbert-Claude Gorin, Peter
Greenberg, Suman Kambhampati, Yoo-Jin Kim, Je-Hwan Lee, Roger Lyons,
Marco Ruggeri, Valeria Santini, Gregory Cheng, Jun Ho Jang, Chien-Yuan Chen,
Souria Dougherty, Frank Mannino, Yasser Mostafa Kamel, Geoffrey Chan, Nicole
Stone, Aristoteles Giagounidis
Numerous clinical studies led by US Oncology
Research affiliated physicians have been prominently featured at conferences
held around the world, including the American Society of Clinical Oncology (ASCO) Annual Meeting, the
San Antonio Breast Cancer Symposium (SABCS), and the European
Society for Medical Oncology (ESMO) European Cancer
Congress. From January to October 2013, more than 100 independent registration
and investigator-initiated studies were published in peer reviewed journals by
investigators associated with US Oncology Research and/or The US Oncology Network. These studies featured forward
looking clinical research topics that are helping advance cancer care today and
discover improved therapies for the cancer care of tomorrow.
About
US Oncology Research
Supported
by McKesson Specialty Health and The US Oncology Network, US Oncology Research
draws from a network of experienced investigators and dedicated clinical staff
who specialize in Phase I through Phase IV oncology clinical trials. US
Oncology Research serves more than 80 research sites and 225 locations managing
about 225 active trials at any given time. Physicians in the research network
have enrolled more than 56,000 patients in nearly 1,300 trials since inception
in 1992 and have played a role in 47 FDA-approved cancer therapies. For more
information call (800) 482-6700 or visit www.usoncology.com/oncologists.
PR Contact
Contact Public Relations